{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T17:17:14Z","timestamp":1725902234842},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.remn.2010.10.012","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T09:52:26Z","timestamp":1298454746000},"page":"77-82","source":"Crossref","is-referenced-by-count":6,"title":["Uso de la PET-18F-FDG en pacientes con sospecha de recurrencia de c\u00e1ncer diferenciado de tiroides por anticuerpos anti-tiroglobulina elevados y rastreo 131I negativo"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Sanz Viedma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Borrego Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Rodr\u00edguez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Navarro Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"V\u00e1zquez Albertino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fern\u00e1ndez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Agudo Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2010.10.012_bib0005","first-page":"78","article-title":"The value of FDG-PET in the follow up of differentiated thyroid c\u00e1ncer: a review of the literature","volume":"50","author":"Stokkel","year":"2006","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2010.10.012_bib0010","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.remn.2010.10.012_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1530\/acta.0.1190373","article-title":"Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome","volume":"119","author":"Pacini","year":"1988","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.remn.2010.10.012_bib0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/BF03349612","article-title":"Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer","volume":"13","author":"Rubello","year":"1990","journal-title":"J Endocrinol Invest."},{"key":"10.1016\/j.remn.2010.10.012_bib0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/thy.1994.4.199","article-title":"Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma","volume":"4","author":"Kumar","year":"1994","journal-title":"Thyroid."},{"key":"10.1016\/j.remn.2010.10.012_bib0030","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1210\/jc.83.4.1121","article-title":"Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma","volume":"83","author":"Spencer","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.remn.2010.10.012_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/clon.1999.9056","article-title":"Thyroglobulin antibodies in differentiated thyroid cancer","volume":"11","author":"Hjiyiannakis","year":"1999","journal-title":"Clin Oncol."},{"key":"10.1016\/j.remn.2010.10.012_bib0040","first-page":"1478","article-title":"Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study","volume":"33","author":"Rubello","year":"1992","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2265.2002.01592.x","article-title":"Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation","volume":"57","author":"Chung","year":"2002","journal-title":"Clin Endocrinol."},{"key":"10.1016\/j.remn.2010.10.012_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/EJE-07-0399","article-title":"The follow-up of patients with CDT and undetectable Tg and AbTg during ablation","volume":"158","author":"Phan","year":"2008","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.remn.2010.10.012_bib0055","first-page":"5","article-title":"PET-FDG in the follow-up of the differentiated thyroid cancer","volume":"24","author":"Franco Baux","year":"2005","journal-title":"Rev Esp Med Nucl."},{"key":"10.1016\/j.remn.2010.10.012_bib0060","first-page":"117","article-title":"Utility of a low-iodide diet in 131I Whole body scanning of patients with differentiated thyroid cancer","volume":"55","author":"Cuenca","year":"2008","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.remn.2010.10.012_bib0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.semnuclmed.2006.03.002","article-title":"Respectives Roles of thyroglobulin, radioiodine Imaging and Positron Emission Tomography in the Assessment of Thyroid Cancer","volume":"36","author":"Lind","year":"2006","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1157\/13102483","article-title":"Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course","volume":"26","author":"Guti\u00e9rrez Cardo","year":"2007","journal-title":"Rev Esp Med Nucl."},{"key":"10.1016\/j.remn.2010.10.012_bib0075","first-page":"S122","article-title":"FDG-PET in the management of patients with well differentiated thyroid carcinoma and positive thyroglobulin autoantibodies. Abstrac in \u201cAnn Congress EAMN 2007\u201d (Copenhagen)","volume":"34","author":"Bogsrud","year":"2007","journal-title":"Eur J Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010","article-title":"Disapperance of Humoral thyroid autoinmunity after complete Removal of thyroid Antigens","volume":"139","author":"Chiovato","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0085","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules an Differenciated Thyroid Cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid."},{"key":"10.1016\/j.remn.2010.10.012_bib0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0212-6982(02)72056-9","article-title":"A proposal for the rational use of the PET in oncology","volume":"21","author":"Borrego Dorado","year":"2002","journal-title":"Rev Esp Med Nucl."},{"key":"10.1016\/j.remn.2010.10.012_bib0095","first-page":"71","article-title":"Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan","volume":"42","author":"Schuluter","year":"2001","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0100","first-page":"1464","article-title":"Clinical impact of 18FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy","volume":"42","author":"Helal","year":"2001","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF00837630","article-title":"Fluorine 18-fluorodexyglucose positron emission tomographyin the follow up of of diffenciated thyroid cancer","volume":"23","author":"Grunwald","year":"1996","journal-title":"Eur J Nucl Med."},{"key":"10.1016\/j.remn.2010.10.012_bib0110","unstructured":"Feine U, Lietnmayer R, Hanke JP, Held J, Worle H, Muller SW. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468\u201372."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212698210002363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212698210002363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T19:33:32Z","timestamp":1560022412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212698210002363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0212698210002363"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2010.10.012","relation":{},"ISSN":["0212-6982"],"issn-type":[{"value":"0212-6982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}